Review
Endocrinology & Metabolism
Anna Solini, Domenico Trico, Stefano Del Prato
Summary: Major cardiovascular outcome trials and real-life observations have shown that GLP-1 receptor agonists (GLP-1RAs) provide clinically relevant cardiovascular protection regardless of GLP-1 homology. GLP-1RAs offer cardioprotective benefits through various mechanisms, including improved insulin secretion and action, weight loss, reduced blood pressure, improved lipid profile, as well as direct effects on the heart and vasculature. The available evidence has led professional and medical societies to recommend GLP-1RAs for reducing cardiovascular risk in people with type 2 diabetes.
Review
Pharmacology & Pharmacy
Artemis Kyriakidou, Theocharis Koufakis, Dimitrios G. Goulis, Yiannis Vasilopoulos, Pantelis Zebekakis, Kalliopi Kotsa
Summary: This review summarizes current evidence related to T2DM risk variants and pharmacogenetics of GLP-1 RAs, particularly focusing on liraglutide. Findings suggest genetic polymorphisms may impact glycemic response and metabolic parameters in patients treated with liraglutide, emphasizing the need for further investigation.
CURRENT PHARMACEUTICAL DESIGN
(2021)
Article
Clinical Neurology
Ronald M. Goldenberg, Alice Y. Y. Cheng, Tess Fitzpatrick, Jeremy D. Gilbert, Subodh Verma, Julia J. Hopyan
Summary: People with diabetes face higher stroke risks and poorer outcomes. GLP-1RAs have been shown to reduce stroke risk in individuals with type 2 diabetes. This study provides evidence supporting the use of GLP-1RAs for stroke reduction and offers practical resources for neurologists considering this treatment.
Article
Endocrinology & Metabolism
Xueyuan Guo, Caihua Sang, Ribo Tang, Chenxi Jiang, Songnan Li, Nian Liu, Deyong Long, Xin Du, Jianzeng Dong, Changsheng Ma
Summary: This meta-analysis aimed to assess the effects of GLP-1RAs on major coronary events in patients with T2DM. The results showed that GLP-1RAs can reduce the risk of myocardial infarction, especially human-based and once-weekly GLP-1RAs. However, no significant benefit was observed for hospitalization for unstable angina or coronary revascularization.
DIABETES OBESITY & METABOLISM
(2023)
Article
Biochemistry & Molecular Biology
Martina Brunner, Othmar Moser, Reingard Raml, Maximilian Haberlander, Beate Boulgaropoulos, Barbara Obermayer-Pietsch, Eva Svehlikova, Thomas R. Pieber, Harald Sourij
Summary: Methods for glucagon analysis in the past were not specific and had a narrow sensitivity range, leading to inaccurate results. Newer methods have shown that actual glucagon levels are lower than previously thought. This study compared glucagon levels in healthy individuals and diabetes patients using two different methods and found that the choice of method can significantly affect the results.
Review
Medicine, Research & Experimental
Habib Yaribeygi, Ali Rashidy-Pour, Stephen L. Atkin, Tannaz Jamialahmadi, Amirhossein Sahebkar
Summary: GLP-1 receptor agonists not only improve glycemic control, but also have potential benefits in improving cognitive performance through multiple molecular mechanisms, which could be particularly beneficial for diabetic patients with cognitive impairments.
Review
Endocrinology & Metabolism
Chloe Wong, Ming Hui Lee, Clyve Yu Leon Yaow, Yip Han Chin, Xin Lei Goh, Cheng Han Ng, Amanda Yuan Ling Lim, Mark Dhinesh Muthiah, Chin Meng Khoo
Summary: This meta-analysis examined the efficacy of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Results showed significant improvements in hepatic fat content, liver biochemistry, body composition, glucose parameters, lipid parameters, insulin sensitivity, and inflammatory markers following treatment with glucagon-like peptide-1 receptor agonists. Glucagon-like peptide-1 receptor agonists were also found to significantly decrease hepatic fat content compared to other treatments, showing promise in improving both diabetes and non-alcoholic fatty liver disease phenotype.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Review
Chemistry, Medicinal
Dihe Cheng, Shuo Yang, Xue Zhao, Guixia Wang
Summary: This article reviews the molecular mechanisms and potential effects of GLP-1 RA in neurodegenerative diseases, particularly diabetes-related Alzheimer's disease and Parkinson's disease.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2022)
Review
Endocrinology & Metabolism
Adie Viljoen, Stephen C. Bain
Summary: The therapeutic benefits of GLP1 for people with type 2 diabetes and/or obesity are well-established. They should replace traditional treatment options and have potential for treating other conditions such as fatty liver disease and Alzheimer's disease.
ENDOCRINOLOGY AND METABOLISM
(2023)
Article
Endocrinology & Metabolism
Tetsuhiko Sato, Yoshinori Azuma, Chikafumi Ozone, Mikako Okazaki, Asami Takeda, Manabu Okada, Kenta Futamura, Takahisa Hiramitsu, Norihiko Goto, Shunji Narumi, Yoshihiko Watarai
Summary: This retrospective cohort study found that the use of GLP-1 receptor agonists in type 2 diabetes patients after kidney transplantation was associated with a lower risk of sustained reduction in kidney function.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Review
Cardiac & Cardiovascular Systems
Pierre Gourdy, Patrice Darmon, Francois Dievart, Jean-Michel Halimi, Bruno Guerci
Summary: GLP-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) have shown cardiovascular protective effects, making them breakthrough therapies for type 2 diabetes mellitus (T2DM). This review discusses the synergies between GLP-1RAs and SGLT2is, highlighting their benefits in treating metabolic-cardiovascular-renal disease in T2DM patients. While SGLT2is have stronger evidence for renal effects, GLP-1RAs are preferable as add-on therapy for T2DM patients with chronic kidney disease and persistent albuminuria or uncontrolled metabolic risks. However, factors such as reimbursement and costs may delay the widespread use of combination therapy. An individualized approach should be taken when considering GLP-1RA plus SGLT2i combination therapy, taking into account individual preferences, costs, toxicity profile, kidney function, glucose-lowering efficacy, weight loss goals, and comorbidities.
CARDIOVASCULAR DIABETOLOGY
(2023)
Article
Endocrinology & Metabolism
Hwi Seung Kim, Taekwan Yoon, Chang Hee Jung, Joong-Yeol Park, Woo Je Lee
Summary: In Korea, the combination of SGLT2i and GLP-1RA has been shown to significantly lower blood sugar levels in patients with type 2 diabetes, with good tolerability and safety.
DIABETES & METABOLISM JOURNAL
(2022)
Review
Clinical Neurology
David M. Williams, Michael Atkinson, Marc Evans
Summary: Stroke is a common and serious complication in people with type 2 diabetes. It is important to understand the underlying mechanisms and explore potential treatments to reduce the risk and improve outcomes for these patients.
Review
Biochemistry & Molecular Biology
Jasna Klen, Vita Dolzan
Summary: Glucagon-like peptide-1 (GLP-1) receptor agonists are a new class of drugs that effectively manage type 2 diabetes and promote weight loss. They have been extensively studied for cardiovascular and renal safety. However, non-responsive patients may have genetic variability in the GLP-1 receptor or signaling pathways.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Chemistry, Medicinal
Yaqin Zhang, Ruofei Chen, Yangyang Jia, Mingwei Chen, Zongwen Shuai
Summary: The study revealed that the GLP-1R agonist exenatide has an effect on coagulation function and platelet aggregation in patients with type 2 diabetes mellitus, which is beneficial for reducing the risk of cardiovascular events.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2021)